Ro was last valued at $5B (post-money). It comes from the $150M Series D-1 of Feb 2022. The company is private, so there is no listed share price.
2 valuations. The latest, $7B post-money, was set by the Series D-1 in Feb 2022.
A private valuation is the price agreed in one transaction. The Ro valuation of $5B is a post-money figure from the Series D-1 dated 15 Feb 2022 — the whole company measured after the $150M raised in that round was already inside it. Subtract the round and the pre-money view of the same deal is $4.8B .
The valuation holds until the next priced round or secondary sale. A private company founded in 2017 with roughly 800 people has no daily price and no order book between rounds.
The routes section explains what is realistically available for a company at this stage.
No. Ro is a private company; its shares do not trade on a public exchange.
The last valuation is $5B.
Lead investors for each round are in the funding timeline.
The closest telehealth peers are on the competitors page.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
